|
|
Sorafenib Tosylate,
|
|
Description Pale brownish to off-white crystalline powder ConformsHeavy metal Not more than 20ppm ConformsLoss on drying Not more than 0. 5% 0. 27%Residue on ignition Not more than 0. 5% 0. 23%Melt po
|
| |
|
Bortezomib
|
|
Appearance: White or off-white crystalline powderIdentification: (by NMR) The Nuclear Magnetic Resonance spectrum of the sample should be the same as that of reference materialLoss on drying: No more
|
| |
|
Erlotinib Hcl
|
|
|
Appearance: Off-white solid.Loss on drying: No more than 0. 5%Purity (HPLC) : Not less than 99. 0%
|
|
|
|
1-Boc-3-Piperidone
|
|
|
1. AppearanceWhite to yellow semi-solid or solid power2: NMR Conforms to structure3. Assay (GC) : NLT96. 5%
|
| |
| |
|
Bicalutamide Intermediate
|
|
|
1. N-[4-Cyano-3- (Trifluoromethyl) phenyl]-3-[ (4-Fluorophenyl) thio]-2-Hydroxy-2-Methyl Propionamide [90356-78-8]2. N-[4-Cyano-3- (trifluoromethyl) phenyl]methacrylamide epoxide[90357-51-0]
|
|
|
|
Deferasirox
|
|
|
Appearance: White or off-white powderSulphated Ash: No more than 0. 1%Heavy Metals:Assay by HPLC:No less than 98. 5%Use: An iron chelating agent
|
| |
| |
|
Letrozole Intermediate
|
|
|
1. 4-[1- (1, 2, 4-triazolyl) -methyl]-benzonitrile2. 4, 4`-Dicyanobenzophenone (intermediate of letrozole)3. 4-[a- (4-cyanophenyl) -hydroxymethyl]-benzonitrile4. 4-[a- (4-cyanophenyl) -chloromethyl]-b
|
|
help
Add to favorite
Favorite products
